 With a second oral GLP-1 for obesity now approved in the U.S., analysts have set to work parsing the blockbuster potential of Eli Lilly’s Foundayo in 2026, as well as the dynamics at play with Novo Nordisk’s equally buzzy Wegovy pill, which launched with a three-month head start on Lilly’s drug in January. 
Content mobilized by FeedBlitz RSS Services, the premium FeedBurner alternative. |
